Chest
Clinical Investigations: Inhaled MedicinesA Comparison of the Availability of Tobramycin for Inhalation From Vented vs Unvented Nebulizers
Section snippets
MATERIALS AND METHODS
The two types of nebulizers chosen were the unvented Hudson 1730 T Up-Draft 11 (Hudson; Temecula, Calif) and the vented Pari LC Jet Plus nebulizer (Pari Respiratory Equipment Inc; Richmond, Va). The Pari LC Jet Plus was chosen because of its particle size distribution5 and because of its one-way valve system that make it relatively simple to direct an through the nebulizer to effectively evaluate nebulizer output. All of the nebulizers tested were driven by a compressor (Pulmo-Aide;
RESULTS
The total output of tobramycin and the output in the RF are shown in Table 1. There were no significant differences in total tobramycin output between the two types of nebulizers without a . The addition of to the vented Pari LC Jet Plus nebulizer decreased the total nebulization time ( , 21.8±2.2 min; , 7.7±1.8 min) (mean±SD) and also changed the particle size distribution such that the RF became larger for >10 L/min (Fig 1). Significant
DISCUSSION
These results demonstrate that the vented nebulizer chosen for this study would have up to a fourfold increase, depending on , in the output of drug during inspiration, thereby minimizing drug loss. In contrast, the unvented nebulizer, while very comparable to the vented nebulizer in the absence of , would show no change in the rate of output during inspiration. What would these results mean for an adolescent CF patient? For a patient with a mean in the order of 15
REFERENCES (18)
- et al.
Pulmonary deposition of aerosols in children with cystic fibrosis
J Pediatr
(1974) - et al.
The choice of jet nebulizer, nebulizing flow and the addition of Ventolin Respiratory Solution affects tobramycin aerosols used in cystic fibrosis
Chest
(1997) - et al.
Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis: The Pulmozyme rhDNase Study Group
Chest
(1995) - et al.
A comparison of pulmonary availability between Ventolin (Albuterol) nebules and Ventolin (Albuterol) Respirator Solution
Chest
(1997) - et al.
Importance of evaporative water losses during standardized nebulized inhalation provacation tests
Chest
(1989) The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers
Int J Pharm
(1995)- et al.
Assessment of jet nebulisers for lung aerosol therapy
Lancet
(1983) - et al.
Quantitative deposition of aerosolized gentamycin in cystic fibrosis
Am Rev Respir Dis
(1987) - et al.
Variability in the measurement of nebulized aerosol deposition in man
Clin Sci
(1991)
Cited by (59)
Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements
2019, Pulmonary Pharmacology and TherapeuticsAssessment of recent nebulizer delivery systems using urinary pharmacokinetics method and aerodynamic characteristics of TOBI<sup>®</sup> nebulized dose following inhalation
2017, Journal of Drug Delivery Science and TechnologyCitation Excerpt :Therefore, new nebuliser systems have been investigated to improve tobramycin aerosol delivery to the peripheral airways and minimize residual drug wastage. Many in-vitro and in-vivo studies have been investigated to achieve these purposes [14–27]. In-vivo studies the pharmacokinetic (PK) methods can provide accurate and reproducible quantification of drug delivery by measuring plasma levels to reflect lung deposition and bioavailability [28,29].
In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems
2016, Pulmonary Pharmacology and TherapeuticsDrug Administration by Inhalation in Children
2012, Kendig and Chernick's Disorders of the Respiratory Tract in ChildrenPulmonary drug delivery systems for antimicrobial agents: facts and myths
2010, International Journal of Antimicrobial Agents
Supported by the Canadian Cystic Fibrosis Foundation. Drs. Meisner and Vadas and Ms. Kelemen are employees of Merck Frosst Canada Inc.